Autologous Stem Cell Transplants Effective for Recurrent Pediatric Brain Tumors (5/27/2009)
Researchers from the Children’s Hospital Los Angeles have reported that high-dose thiotepa-based autologous transplant regimens are effective in children with recurrent medulloblastoma (MB) and supratentorial primitive neuroectodermal tumors (PNET). The details of this study appeared in an early online publication in Cancer on April 28, 2009.

Five-year Follow-up Confirms Benefit of Adding Temodar® Radiotherapy for Glioblastoma (3/24/2009)
Researchers affiliated with EORTC-NCIF randomized trial have reported that a longer follow-up confirms the benefit of adding Temodar® (temozolomide) to adjuvant radiotherapy for the treatment of patients with glioblastoma multiforme (GBM). The details of this study appeared in an early online publication in the Lancet Oncology on March 9, 2009.

Tarceva® and Temodar® plus Radiation Improves Survival in Glioblastoma Multiforme (2/12/2009)
Researchers from the University of California at San Francisco have reported that the addition of Tarceva® (erlotinib) and Temodar® (temozolomide) during and after radiation therapy improves survival in patients with newly diagnosed glioblastoma multiforme (GBM) and gliosarcoma. The details of this study appeared in the February 1, 2009 issue of the Journal of Clinical Oncology.

Cell Phones Do Not Increase Risk of Developing Meningioma (9/29/2008)
Researchers from Finland, Denmark, the United Kingdom, Sweden, and Norway have reported that long-term data do not indicate an association between the use of cell phones and an increased risk of meningioma. The details of this study appeared in an early online publication in the International Journal of Epidemiology on August 2, 2008.

Intravenous Rituxan® Effective in Primary Central Nervous System Lymphomas (9/16/2008)
Researchers affiliated with the NCI-sponsored New Approaches to Brain Tumor Therapy (NABTT) consortium have reported that intravenous Rituxan® (rituximab) may be effective in the treatment of primary central nervous system lymphoma (PCNSL). These results were presented at the 2008 annual meeting of the American Society of Clinical Oncology in May, 2008.